Author:
Christov Konstantin,Wiehle Ronald D.
Reference74 articles.
1. Attardi B, Burgenson J, Hild S, Reel JR, Blye RP (2002) CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent anti-progestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188:111–123
2. Attardi B, Burgenson J, Hild SA, Reel JR (2004) In vitro antiprogestational- antiglucocorticoid activity and progestin and glucocorticoid receptor binding activity of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 88:277–288
3. Bakker GH, Setyono-Han B, Henkelman MS et al (1987) Comparison of the actions of the anti-progestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71:1021–1027
4. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM (1989) Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing animal tumors. Endocrinology 125:1593–1598
5. Bakker GH, Setyono-Han B, Portengen H et al (1990) Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789–794